Related Experiment Video
Updated: Oct 17, 2025
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
Microspheres present comparable efficacy and safety profiles compared with polyvinyl alcohol for bronchial artery
Zhigang Fu1, Xun Li2, Fei Cai1
1Department of Radiology, Yichang Central People's Hospital, First College of Clinical Medical Science, China Three Gorges University, 183 Yiling Road, Yichang, 443003, China.
Background:
The present study aimed to compare the efficacy and safety profiles of microspheres versus (vs.) polyvinyl alcohol (PVA) for bronchial artery embolization (BAE) treatment in patients with hemoptysis.
Methods:
Totally, 152 patients with hemoptysis who were about to receive BAE treatment were consecutively enrolled and divided into microspheres group (N = 62) and PVA group (N = 90). Technical success and clinical success were assessed after BAE procedure, and the hemoptysis-recurrence status, survival status and adverse events were recorded during follow-up.
Results:
Technical success rates were both 100% in microspheres group and PVA group; clinical success rate (96.8% vs. 100.0%, P = 0.165), 6-month (9.7% vs. 7.8%, P = 0.681) and 1-year (9.7% vs. 8.9%, P = 0.869) hemoptysis recurrence rate, 6-month (4.8% vs. 2.2%, P = 0.374) and 1-year (4.8% vs. 3.3%, P = 0.639) mortality were similar between microspheres group and PVA group. Furthermore, hemoptysis-free survival (P = 0.488) and overall survival (P = 0.321) were of no difference between two groups. In addition, all adverse events were mild, and there was no difference of adverse events between two groups (all P > 0.05). These data were validated by further multivariate regression analysis.
Conclusions:
Microspheres present comparable efficacy and safety profiles compared with PVA for the BAE treatment in patients with hemoptysis, providing evidence for embolic agent selection.
Insights
Microspheres and polyvinyl alcohol (PVA) show similar effectiveness and safety for bronchial artery embolization (BAE) in treating hemoptysis. This study provides evidence for selecting embolic agents in BAE procedures.
Area of Science:
- Interventional Radiology
- Vascular Medicine
- Pulmonary Medicine
Background:
- Hemoptysis is a critical condition requiring effective treatment.
- Bronchial artery embolization (BAE) is a primary intervention for hemoptysis management.
- The choice of embolic agent impacts BAE outcomes.
Purpose of the Study:
- To compare the efficacy and safety of microspheres versus polyvinyl alcohol (PVA) in BAE for hemoptysis.
- To evaluate clinical success, recurrence rates, mortality, and adverse events.
- To provide data for informed embolic agent selection in BAE.
Main Methods:
- A comparative study involving 152 patients with hemoptysis undergoing BAE.
- Patients were divided into two groups: microspheres (N=62) and PVA (N=90).
- Outcomes assessed included technical and clinical success, hemoptysis recurrence, survival status, and adverse events during follow-up.
Main Results:
- Both microspheres and PVA achieved 100% technical success rates.
- Clinical success rates, hemoptysis recurrence, and mortality rates at 6 months and 1 year were similar between groups.
- No significant differences were observed in hemoptysis-free survival or overall survival; all adverse events were mild.
Conclusions:
- Microspheres demonstrate comparable efficacy and safety to PVA for BAE in hemoptysis patients.
- The findings support the use of microspheres as a viable alternative to PVA.
- This study contributes valuable evidence for embolic agent selection in BAE procedures.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...